Ampersand Capital Partners to acquire Vibalogics

3 Jun 2019

Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products.

Vibalogics, a CDMO focused on complex live biological products, is being acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Ampersand’s growth investment will be used to expand Vibalogics’ capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products.

Ampersand Capital Partners to acquire Vibalogics

Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines. With a specific focus on viruses, live bacteria, and aseptic processing, the company’s 50 employees work in full compliance with international GMP standards in a BSL-2 classified state of the art, 27,000 sq. ft. (2,500 m2) facility in Cuxhaven, Germany.

Stefan Beyer, CEO of Vibalogics commented: “With the benefit of Ampersand as our partner, Vibalogics will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities. The partnership solidifies Vibalogics’ existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer and genetic disorders. We are very pleased to have Ampersand on board as we take Vibalogics through to its next phase of growth.”

David Anderson, General Partner at Ampersand said: “Vibalogics is a leading company in its field. Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company. We are looking forward to working with the team at Vibalogics to accelerate and continue its success in delivering cutting edge therapies to patients in need.”

Read More

Related tags

Market News

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
Janssen opens new biomanufacturing building in Ireland

Janssen opens new biomanufacturing building in Ireland

8 Oct 2019

Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Allergan expands Refresh eye treatment portfolio

Allergan expands Refresh eye treatment portfolio

7 Oct 2019

A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

Read more 
BASF strengthens biotechnology footprint to enter natural F&F ingredients market

BASF strengthens biotechnology footprint to enter natural F&F ingredients market

3 Oct 2019

Market entrance with biotech-based natural vanillin, valencene and nootkatone.

Read more 
Unidose device approved for Tosymra sumatriptan spray

Unidose device approved for Tosymra sumatriptan spray

3 Oct 2019

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

Read more 
One-stop-platform for plant-based nutraceuticals

One-stop-platform for plant-based nutraceuticals

2 Oct 2019

In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

Read more 
BASF's new bioactive ingredient the wellness elixir for healthy skin

BASF's new bioactive ingredient the wellness elixir for healthy skin

1 Oct 2019

The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more